<p>最近幾周，全球市場顯示出樂觀跡象，因為美國和中國之間的貿易緊張局勢似乎正在緩解，這推動了美國股市的上漲，並導致納斯達克綜合指數等主要指數的增長。在這種謹慎經濟復甦的背景下，投資者通常會尋找內部持股比例較高的成長型公司，因為這些股票可以提供管理層對其業務發展軌跡的信心以及在市場不確定性下的潛在韌性。</p>
<h3>全球內部持股比例高的十大成長型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>AcrelLtd (SZSE:300286)</td>
<td>34.2%</td>
<td>34.9%</td>
</tr>
<tr>
<td>Seojin SystemLtd (KOSDAQ:A178320)</td>
<td>32.1%</td>
<td>39.3%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.8%</td>
<td>43.1%</td>
</tr>
<tr>
<td>Vow (OB:VOW)</td>
<td>13.1%</td>
<td>111.2%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>36.4%</td>
<td>40.2%</td>
</tr>
<tr>
<td>Global Tax Free (KOSDAQ:A204620)</td>
<td>20.8%</td>
<td>35.1%</td>
</tr>
<tr>
<td>CD Projekt (WSE:CDR)</td>
<td>29.7%</td>
<td>37.4%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>22.6%</td>
<td>88.2%</td>
</tr>
<tr>
<td>Nordic Halibut (OB:NOHAL)</td>
<td>29.7%</td>
<td>60.7%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>13.6%</td>
<td>74.7%</td>
</tr>
</tbody>
</table>
<p>點擊此處查看我們快速增長的全球內部持股比例高的 856 只股票的完整列表。</p>
<p>讓我們更仔細地看看我們從篩選公司中挑選的幾隻股票。</p>
<h2>潤本股份 (SHSE:603193)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 潤本股份有限公司專注於蚊蟲驅避產品、嬰兒護理產品和精油產品的研究、生產和銷售，市值為 143.5 億人民幣。</p>
<p><strong>運營：</strong> 公司的收入主要來自個人護理產品部門，產生了 13.9 億人民幣的收入。</p>
<p><strong>內部持股比例：</strong> 29.6%</p>
<p><strong>收入增長預測：</strong> 每年 23%。</p>
<p>潤本股份的收入預計每年增長 23%，超過了更廣泛的中國市場。儘管預期的 ROE 為 17.8% 低於基準，但其收益增長仍然顯著，達到每年 23.5%，儘管略低於市場平均水平。最近的第一季度業績顯示出強勁表現，銷售額從去年同期的 1.6668 億人民幣上升至 2.4003 億人民幣，淨收入增加至 4420 萬人民幣，反映出強勁的運營勢頭，近期沒有報告重大內部交易活動。</p>
<ul>
<li>解鎖我們對潤本股份股票分析的全面見解，詳見本增長報告。</li>
<li>我們的潤本股份估值報告中的分析暗示其股價相較於估計價值被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/41571584-04fe-437d-8261-8c6c369a4bae/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/41571584-04fe-437d-8261-8c6c369a4bae/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:603193 截至 2025 年 4 月的收益和收入增長</p>
<h2>武漢光電 (SZSE:002414)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 武漢光電有限公司專注於亞洲紅外熱成像技術的研究、開發、生產和銷售，市值為 322.4 億人民幣。</p>
<p><strong>運營：</strong> 公司的收入主要來自其他電子設備製造，金額為 26.2 億人民幣，以及技術服務行業，貢獻了 4278 萬人民幣。</p>
<p><strong>內部持股比例：</strong> 27.1%</p>
<p><strong>收入增長預測：</strong> 每年 27.6%。</p>
<p>武漢光電的收入預計每年增長 27.6%，超過更廣泛的中國市場增長率。儘管預期的 ROE 為 9.5% 較低，但預計公司將在三年內實現盈利，表明其市場利潤增長潛力高於平均水平。最近的第一季度業績顯示出顯著改善，銷售額從 4.6797 億人民幣增加至 6.8076 億人民幣，淨收入大幅上升至 8355 萬人民幣，近期沒有報告重大內部交易活動。</p>
<ul>
<li>在這裏深入瞭解武漢光電的完整分析未來增長報告。</li>
<li>我們的估值報告顯示武漢光電可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6a0b0920-be46-4387-a40e-f0d75583886e/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6a0b0920-be46-4387-a40e-f0d75583886e/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:002414 截至 2025 年 4 月的收益和收入增長</p>
<h2>博創科技 (SZSE:300548)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 博創科技有限公司從事光通信領域集成光電設備的研究、開發、生產和銷售，市值為 106.5 億人民幣。</p>
<p><strong>運營：</strong> 公司的收入部分包括來自電信市場的 6.6968 億人民幣和來自數據通信、消費和工業互聯的 10.7 億人民幣。</p>
<p><strong>內部持股比例：</strong> 11.5%</p>
<p><strong>收入增長預測：</strong> 每年 21.6%。</p>
<p>博創科技預計每年收入增長 21.6%，超過中國市場的 12.6% 增長率，預計收益將顯著增長，每年達到 42.4%。儘管其股價相較於估計的公允價值有顯著折扣，並經歷了股價波動，博創在 2024 年報告的全年銷售額為 17.5 億人民幣，較前一年的 16.8 億人民幣有所上升，儘管淨收入略微下降至 7207 萬人民幣，低於 8147 萬人民幣。</p>
<ul>
<li>在這裏深入瞭解博創科技的具體情況，查看我們的詳細增長預測報告。</li>
<li>根據我們的估值報告，博創科技的股價可能偏高。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/273e61dc-0e7f-4c24-8955-0d5ce0353744/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/273e61dc-0e7f-4c24-8955-0d5ce0353744/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:300548 截至 2025 年 4 月的收益和收入增長</p>
<h2>抓住機會</h2>
<ul>
<li>在這裏探索我們快速增長的全球公司中高管持股比例高的 856 個名字。</li>
<li>想要探索一些替代方案嗎？稀土金屬是大多數高科技設備、軍事和防禦系統以及電動車的原材料。全球競賽正在進行，以確保這些關鍵礦物的供應。搶先一步，發現這少數開採這一重要戰略資源的 23 只最佳稀土金屬股票。</li>
</ul>
<p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。該分析僅考慮由內部人士直接持有的股票，不包括通過其他工具如公司和/或信託實體間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
<p>如果您想交易潤本股份，請在專業人士信賴的最低成本平台 Interactive Brokers 開設賬户。</p>
<p>IBKR 在 200 多個國家和地區擁有客户，並可訪問 160 個市場，讓您可以通過一個集成賬户交易股票、期權、期貨、外匯、債券和基金。</p>
<p>享受無隱藏費用，無賬户最低要求，外匯轉換率低至 0.03%，遠低於大多數經紀商提供的費用。</p>
<p>贊助內容</p>

潤本股份

長芯博創

<p>三家全球增長公司擁有較高的內部持股比例，預計將實現顯著的收入增長：潤本股份（內部持股 29.6%，收入增長預測 23%）、武漢光電（內部持股 27.1%，收入增長預測 27.6%）和博創科技（內部持股 11.5%，收入增長預測 21.6%）。在經濟條件改善的背景下，這些公司有望超越更廣泛的市場，並因管理層對其業務發展軌跡的信心而吸引投資者的關注</p>

<p>In recent weeks, global markets have shown signs of optimism as trade tensions between the U.S. and China appear to be easing, boosting U.S. equities and leading to gains in major indices such as the Nasdaq Composite. Amid this backdrop of cautious economic recovery, investors often look for growth companies with strong insider ownership, as these stocks can offer insights into management's confidence in their business trajectory and potential resilience against market uncertainties.</p>
<div class="lb-trans"><p>最近幾周，全球市場顯示出樂觀跡象，因為美國和中國之間的貿易緊張局勢似乎正在緩解，這推動了美國股市的上漲，並導致納斯達克綜合指數等主要指數的增長。在這種謹慎經濟復甦的背景下，投資者通常會尋找內部持股比例較高的成長型公司，因為這些股票可以提供管理層對其業務發展軌跡的信心以及在市場不確定性下的潛在韌性。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership Globally</h3>
<div class="lb-trans"><h3>全球內部持股比例高的十大成長型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>AcrelLtd (SZSE:300286)</td>
<td>34.2%</td>
<td>34.9%</td>
</tr>
<tr>
<td>Seojin SystemLtd (KOSDAQ:A178320)</td>
<td>32.1%</td>
<td>39.3%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.8%</td>
<td>43.1%</td>
</tr>
<tr>
<td>Vow (OB:VOW)</td>
<td>13.1%</td>
<td>111.2%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>36.4%</td>
<td>40.2%</td>
</tr>
<tr>
<td>Global Tax Free (KOSDAQ:A204620)</td>
<td>20.8%</td>
<td>35.1%</td>
</tr>
<tr>
<td>CD Projekt (WSE:CDR)</td>
<td>29.7%</td>
<td>37.4%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>22.6%</td>
<td>88.2%</td>
</tr>
<tr>
<td>Nordic Halibut (OB:NOHAL)</td>
<td>29.7%</td>
<td>60.7%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>13.6%</td>
<td>74.7%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>AcrelLtd (SZSE:300286)</td>
<td>34.2%</td>
<td>34.9%</td>
</tr>
<tr>
<td>Seojin SystemLtd (KOSDAQ:A178320)</td>
<td>32.1%</td>
<td>39.3%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.8%</td>
<td>43.1%</td>
</tr>
<tr>
<td>Vow (OB:VOW)</td>
<td>13.1%</td>
<td>111.2%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>36.4%</td>
<td>40.2%</td>
</tr>
<tr>
<td>Global Tax Free (KOSDAQ:A204620)</td>
<td>20.8%</td>
<td>35.1%</td>
</tr>
<tr>
<td>CD Projekt (WSE:CDR)</td>
<td>29.7%</td>
<td>37.4%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>22.6%</td>
<td>88.2%</td>
</tr>
<tr>
<td>Nordic Halibut (OB:NOHAL)</td>
<td>29.7%</td>
<td>60.7%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>13.6%</td>
<td>74.7%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 856 stocks from our Fast Growing Global Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>點擊此處查看我們快速增長的全球內部持股比例高的 856 只股票的完整列表。</p>
</div><p>Let's take a closer look at a couple of our picks from the screened companies.</p>
<div class="lb-trans"><p>讓我們更仔細地看看我們從篩選公司中挑選的幾隻股票。</p>
</div><h2>Runben Biotechnology (SHSE:603193)</h2>
<div class="lb-trans"><h2>潤本股份 (SHSE:603193)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Runben Biotechnology Co., Ltd. focuses on the research, production, and sale of mosquito repellent products, baby care products, and essential oil products with a market cap of CN¥14.35 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 潤本股份有限公司專注於蚊蟲驅避產品、嬰兒護理產品和精油產品的研究、生產和銷售，市值為 143.5 億人民幣。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its personal products segment, which generated CN¥1.39 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自個人護理產品部門，產生了 13.9 億人民幣的收入。</p>
</div><p><strong>Insider Ownership:</strong> 29.6%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 29.6%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 23% p.a.</p>
<div class="lb-trans"><p><strong>收入增長預測：</strong> 每年 23%。</p>
</div><p>Runben Biotechnology's revenue is forecast to grow 23% annually, outpacing the broader CN market. Despite a lower-than-benchmark expected ROE of 17.8%, its earnings growth remains significant at 23.5% per year, although slightly below the market average. Recent Q1 results showed strong performance with sales rising to CNY 240.03 million from CNY 166.68 million year-over-year and net income increasing to CNY 44.2 million, reflecting robust operational momentum without substantial insider trading activity reported recently.</p>
<div class="lb-trans"><p>潤本股份的收入預計每年增長 23%，超過了更廣泛的中國市場。儘管預期的 ROE 為 17.8% 低於基準，但其收益增長仍然顯著，達到每年 23.5%，儘管略低於市場平均水平。最近的第一季度業績顯示出強勁表現，銷售額從去年同期的 1.6668 億人民幣上升至 2.4003 億人民幣，淨收入增加至 4420 萬人民幣，反映出強勁的運營勢頭，近期沒有報告重大內部交易活動。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Runben Biotechnology stock in this growth report.</li>
<li>The analysis detailed in our Runben Biotechnology valuation report hints at an inflated share price compared to its estimated value.</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖我們對潤本股份股票分析的全面見解，詳見本增長報告。</li>
<li>我們的潤本股份估值報告中的分析暗示其股價相較於估計價值被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/41571584-04fe-437d-8261-8c6c369a4bae/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/41571584-04fe-437d-8261-8c6c369a4bae/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:603193 Earnings and Revenue Growth as at Apr 2025</p>
<div class="lb-trans"><p>SHSE:603193 截至 2025 年 4 月的收益和收入增長</p>
</div><h2>Wuhan Guide Infrared (SZSE:002414)</h2>
<div class="lb-trans"><h2>武漢光電 (SZSE:002414)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Wuhan Guide Infrared Co., Ltd. focuses on the research, development, production, and sale of infrared thermal imaging technology in Asia with a market cap of CN¥32.24 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 武漢光電有限公司專注於亞洲紅外熱成像技術的研究、開發、生產和銷售，市值為 322.4 億人民幣。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from Other Electronic Equipment Manufacturing, amounting to CN¥2.62 billion, and Technical Service Industry, contributing CN¥42.78 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自其他電子設備製造，金額為 26.2 億人民幣，以及技術服務行業，貢獻了 4278 萬人民幣。</p>
</div><p><strong>Insider Ownership:</strong> 27.1%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 27.1%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 27.6% p.a.</p>
<div class="lb-trans"><p><strong>收入增長預測：</strong> 每年 27.6%。</p>
</div><p>Wuhan Guide Infrared's revenue is projected to grow 27.6% annually, surpassing the broader CN market growth rate. Despite a low forecasted ROE of 9.5%, the company is expected to achieve profitability within three years, indicating above-average market profit growth potential. Recent Q1 results demonstrated significant improvement, with sales increasing to CNY 680.76 million from CNY 467.97 million and net income rising sharply to CNY 83.55 million, with no substantial insider trading activity reported recently.</p>
<div class="lb-trans"><p>武漢光電的收入預計每年增長 27.6%，超過更廣泛的中國市場增長率。儘管預期的 ROE 為 9.5% 較低，但預計公司將在三年內實現盈利，表明其市場利潤增長潛力高於平均水平。最近的第一季度業績顯示出顯著改善，銷售額從 4.6797 億人民幣增加至 6.8076 億人民幣，淨收入大幅上升至 8355 萬人民幣，近期沒有報告重大內部交易活動。</p>
</div><ul>
<li>Delve into the full analysis future growth report here for a deeper understanding of Wuhan Guide Infrared.</li>
<li>Our valuation report here indicates Wuhan Guide Infrared may be overvalued.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏深入瞭解武漢光電的完整分析未來增長報告。</li>
<li>我們的估值報告顯示武漢光電可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6a0b0920-be46-4387-a40e-f0d75583886e/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/6a0b0920-be46-4387-a40e-f0d75583886e/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:002414 Earnings and Revenue Growth as at Apr 2025</p>
<div class="lb-trans"><p>SZSE:002414 截至 2025 年 4 月的收益和收入增長</p>
</div><h2>Broadex Technologies (SZSE:300548)</h2>
<div class="lb-trans"><h2>博創科技 (SZSE:300548)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Broadex Technologies Co., Ltd. engages in the research, development, production, and sale of integrated optoelectronic devices for optical communications both in China and internationally, with a market cap of CN¥10.65 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 博創科技有限公司從事光通信領域集成光電設備的研究、開發、生產和銷售，市值為 106.5 億人民幣。</p>
</div><p><strong>Operations:</strong> The company's revenue segments include CN¥669.68 million from the Telecom Market and CN¥1.07 billion from Data communications, consumer and industrial interconnection.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入部分包括來自電信市場的 6.6968 億人民幣和來自數據通信、消費和工業互聯的 10.7 億人民幣。</p>
</div><p><strong>Insider Ownership:</strong> 11.5%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 11.5%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 21.6% p.a.</p>
<div class="lb-trans"><p><strong>收入增長預測：</strong> 每年 21.6%。</p>
</div><p>Broadex Technologies is forecasted to see revenue growth of 21.6% annually, outpacing the CN market's 12.6% growth rate, with earnings expected to grow significantly at 42.4% per year. Despite trading at a substantial discount to its estimated fair value and experiencing share price volatility, Broadex reported full-year sales of CNY 1.75 billion for 2024, up from CNY 1.68 billion in the previous year, though net income decreased slightly to CNY 72.07 million from CNY 81.47 million.</p>
<div class="lb-trans"><p>博創科技預計每年收入增長 21.6%，超過中國市場的 12.6% 增長率，預計收益將顯著增長，每年達到 42.4%。儘管其股價相較於估計的公允價值有顯著折扣，並經歷了股價波動，博創在 2024 年報告的全年銷售額為 17.5 億人民幣，較前一年的 16.8 億人民幣有所上升，儘管淨收入略微下降至 7207 萬人民幣，低於 8147 萬人民幣。</p>
</div><ul>
<li>Dive into the specifics of Broadex Technologies here with our thorough growth forecast report.</li>
<li>According our valuation report, there's an indication that Broadex Technologies' share price might be on the expensive side.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏深入瞭解博創科技的具體情況，查看我們的詳細增長預測報告。</li>
<li>根據我們的估值報告，博創科技的股價可能偏高。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/273e61dc-0e7f-4c24-8955-0d5ce0353744/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/273e61dc-0e7f-4c24-8955-0d5ce0353744/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:300548 Earnings and Revenue Growth as at Apr 2025</p>
<div class="lb-trans"><p>SZSE:300548 截至 2025 年 4 月的收益和收入增長</p>
</div><h2>Seize The Opportunity</h2>
<div class="lb-trans"><h2>抓住機會</h2>
</div><ul>
<li>Explore the 856 names from our Fast Growing Global Companies With High Insider Ownership screener here.</li>
<li>Want To Explore Some Alternatives? Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 23 best rare earth metal stocks of the very few that mine this essential strategic resource.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏探索我們快速增長的全球公司中高管持股比例高的 856 個名字。</li>
<li>想要探索一些替代方案嗎？稀土金屬是大多數高科技設備、軍事和防禦系統以及電動車的原材料。全球競賽正在進行，以確保這些關鍵礦物的供應。搶先一步，發現這少數開採這一重要戰略資源的 23 只最佳稀土金屬股票。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。該分析僅考慮由內部人士直接持有的股票，不包括通過其他工具如公司和/或信託實體間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
</div><p>If you're looking to trade Runben Biotechnology, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.</p>
<div class="lb-trans"><p>如果您想交易潤本股份，請在專業人士信賴的最低成本平台 Interactive Brokers 開設賬户。</p>
</div><p>With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.</p>
<div class="lb-trans"><p>IBKR 在 200 多個國家和地區擁有客户，並可訪問 160 個市場，讓您可以通過一個集成賬户交易股票、期權、期貨、外匯、債券和基金。</p>
</div><p>Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.</p>
<div class="lb-trans"><p>享受無隱藏費用，無賬户最低要求，外匯轉換率低至 0.03%，遠低於大多數經紀商提供的費用。</p>
</div><p>Sponsored Content</p>
<div class="lb-trans"><p>贊助內容</p>
</div>

三家全球增長型公司，內部持股比例高，預計收入增長可達 27%